UK Begins Human Trial for H5N1 Bird Flu Vaccine Targeting Potential Pandemic Strain
The United Kingdom has commenced human trials for a vaccine designed to protect against a potential bird flu pandemic. Volunteers have received the immunisation, which targets the H5N1 flu strain, a variant responsible for widespread infections in bird populations globally and detected in some mammals.
Currently, the risk to humans remains low, with nearly all confirmed human cases attributed to direct contact with infected animals. The vaccine employs the same mRNA technology utilised in existing Covid-19 jabs, a method lauded by scientists for its capacity to facilitate rapid, large-scale vaccine production should a pandemic arise.
The trial seeks to recruit 4,000 participants, primarily individuals working in the poultry industry and those over 65, identified as the most vulnerable demographics. Three-quarters of these volunteers are being enrolled at 26 sites across England and Scotland, with the remaining participants located in the United States.
Dr Rebecca Clark, the trial’s national co-ordinating investigator, highlighted the H5N1 strain's ongoing evolution and spread across animal species. She cautioned that while human-to-human transmission is not yet prevalent, it must be considered a genuine possibility, underscoring the trial as a proactive measure against such an eventuality and any future pandemic it might precipitate.
Since 2024, 116 confirmed human cases of H5N1 have been reported globally, almost exclusively linked to close animal contact. The study will evaluate the vaccine's safety profile and its ability to elicit a robust immune response. Successful outcomes could lead to its licensure for deployment if circumstances necessitate.
Professor Lucy Chappell, Chief Scientific Adviser at the Department of Health and Social Care, stated the trial bolsters national pandemic resilience. Should the vaccine be required, manufacturing would occur at Moderna’s new Oxfordshire facility, capable of producing 100 million doses annually, expandable to 250 million doses during a pandemic.
Traditional flu vaccine production, relying on virus growth in eggs, faces challenges with virulent avian flu strains that can destroy the eggs. The Covid-19 pandemic demonstrated the mRNA platform’s effectiveness in preventing severe illness and its adaptability to evolving viral strains. While flu pandemics are inevitable, the timing of the next global outbreak is uncertain, with the H5N1 strain representing one potential catalyst.
Historically, the 2009 'swine flu' pandemic was relatively mild, whereas the 1918 'Spanish flu' claimed approximately 50 million lives worldwide. Around 1,000 confirmed human H5N1 cases have been reported to the World Health Organisation since 2003, with nearly half proving fatal. More recent US strains have presented milder symptoms, primarily eye inflammation.
In August 2025, the US government cut USD#500 million in mRNA vaccine funding following comments from Health Secretary Robert F. Kennedy Jr., a vaccine sceptic, who asserted that 'mRNA technology poses more risks than benefits' for respiratory viruses. The Coalition for Epidemic Preparedness Innovations (CEPI) has since provided GBP#40 million in funding for the trial.
Under this arrangement, Moderna has committed to guaranteeing prompt and affordable vaccine supplies to low and middle-income nations in any future pandemic. CEPI stated this initiative aims to mitigate the 'vaccine nationalism' observed during the Covid-19 pandemic, when affluent nations monopolised early vaccine supplies, leaving millions in less developed countries unprotected.
